Gennex Laboratories Current Share Price | Gennex Laboratories Stock Screener
GENNEX
Pharmaceuticals
Gennex Laboratories Current Stock Price Today
Live Share Price BSE
₹10.27
▼
-0.16 (-1.53%)
As of September 18, 2026, the live Gennex Laboratories share price (BSE: GENNEX) is ₹10.27, down 1.53% from the previous close, with shares trading between ₹10.00 and ₹10.50 in today's trading session, and a 52-week range of ₹7.13–₹17.02.
Browse GENNEX financial statements to support your investment research.
Use the Gennex Laboratories stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Gennex Laboratories Market Cap
₹269.63 Cr.
GENNEX P/E Ratio (TTM)
13.19
Gennex Laboratories P/B Ratio
1.22
EPS (TTM)
₹0.76
Dividend Yield
-
Debt to Equity
0.04
GENNEX 52 Week High
₹17.02
Gennex Laboratories 52 Week Low
₹7.13
Operating Margin
11.00%
Profit Margin
11.90%
GENNEX Revenue (TTM)
₹42.00
EBITDA
₹6.00
Net Income
₹5.00
Total Assets
₹349.00
Total Equity
₹223.00
Gennex Laboratories Current Share Price Chart
Track the current Gennex Laboratories share price and stock price with an interactive chart. Analyse GENNEX price trends, trading volume, historical performance, and volatility across different timeframes — the complete Gennex Laboratories stock quote in one place.
Gennex Laboratories Company Profile - Fundamental Screener
Screen Gennex Laboratories company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for GENNEX shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE509C01026
Gennex Laboratories Balance Sheet Screener
Screen GENNEX balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 349 | 256 | 230 | 132 | 68 | 59 | 57 | 52 | 51 | 49 |
| Current Assets | 265 | 181 | 162 | 49 | 47 | 38 | 35 | 29 | 28 | 26 |
| Fixed Assets | 74 | 60 | 56 | 74 | 14 | 14 | 15 | 16 | 16 | 16 |
| Liabilities | ||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 43 | 17 | 13 | 16 | 0 | 0 | 0 | 1 | 1 | 1 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 223 | 195 | 177 | 87 | 44 | 40 | 36 | 34 | 32 | 31 |
| Share Capital | 24 | 23 | 23 | 18 | 13 | 13 | 13 | 13 | 13 | 13 |
| Reserves & Surplus | 198 | 158 | 142 | 62 | 31 | 27 | 23 | 21 | 19 | 18 |
Gennex Laboratories Income Statement Screener - Profit & Revenue Analysis
Screen Gennex Laboratories income statement and profit fundamentals.
Analyze GENNEX quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Gennex Laboratories share price evaluation.
| Item | 2026-Jun | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec | 2023-Sept | 2023-Jun | 2023-Mar | 2022-Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 42 | 62 | 40 | 37 | 37 | 44 | 38 | 32 | 31 | 34 | 19 | 18 | 17 | 19 | 14 |
| Expenses | 36 | 55 | 35 | 32 | 29 | 39 | 33 | 26 | 24 | 29 | 17 | 12 | 11 | 17 | 13 |
| EBITDA | 6 | 7 | 6 | 6 | 7 | 6 | 5 | 6 | 7 | 4 | 3 | 5 | 5 | 1 | 1 |
| Operating Profit % | 11.00% | 9.00% | 14.00% | 15.00% | 15.00% | 5.00% | 13.00% | 18.00% | 15.00% | 13.00% | 13.00% | 29.00% | 31.00% | 7.00% | 8.00% |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 |
| Profit Before Tax | 5 | 5 | 7 | 6 | 6 | 4 | 6 | 6 | 6 | 5 | 4 | 4 | 4 | 3 | 2 |
| Tax | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 |
| Net Profit | 5 | 5 | 6 | 6 | 5 | 3 | 5 | 5 | 5 | 5 | 3 | 3 | 3 | 2 | 1 |
| EPS | 0.19 | 0.16 | 0.22 | 0.21 | 0.22 | 0.14 | 0.22 | 0.21 | 0.19 | 0.16 | 0.16 | 0.16 | 0.16 | 0.19 | 0.07 |
Gennex Laboratories Cash Flow Screener - Liquidity Fundamentals
Screen GENNEX cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March |
|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | -11 | -47 | 24 | 12 | -1 | -2 | 2 | 3 | 0 |
| Investing Activities | 1 | 19 | -38 | -3 | 0 | 0 | -1 | -1 | -1 |
| Financing Activities | 5 | 74 | 21 | -2 | 2 | 0 | 1 | -2 | 1 |
| Net Cash Flow | -5 | 46 | 6 | 8 | 0 | -2 | 2 | 0 | 0 |
Gennex Laboratories Shareholding Pattern Screener
See Gennex Laboratories shareholding pattern with promoter, FII, and DII holdings.
Check Gennex Laboratories promoter holding and ownership changes for GENNEX on TickJournal.
| Item | 2026-Mar | 2026-Jun | 2025-Mar | 2025-Jun | 2025-Jul | 2025-Sept | 2025-Dec | 2024-Feb |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 23.63% | 23.63% | 18.42% | 19.83% | 23.62% | 23.62% | 23.62% | 18.42% |
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 55.79% | 56.49% | 62.19% | 61.90% | 58.97% | 59.34% | 56.47% | 58.81% |
| Other Holding | 20.58% | 19.88% | 19.39% | 18.28% | 17.41% | 17.04% | 19.91% | 22.78% |
| Shareholder Count | 84,133 | 82,886 | 92,326 | 91,183 | 91,183 | 90,320 | 86,306 | 69,750 |
Gennex Laboratories Share Dividend Screener - Share Yield Analysis
Check Gennex Laboratories dividend history with payout and yield data.
View Gennex Laboratories dividend details including ex-dates and amounts for GENNEX stock.
Gennex Laboratories Stock Index Membership
See which indices include Gennex Laboratories stock.
Check GENNEX index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
Gennex Laboratories Market Events Screener - Corporate Actions
Get Gennex Laboratories corporate actions including splits, bonuses, and buybacks.
Check Gennex Laboratories stock events that may affect GENNEX share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-09-30 | 2026-09-30 | Annual General Meeting | NA | -6.44% |
| 2026-08-14 | 2026-08-14 | Quarterly Result Announcement | NA | 6.23% |
| 2026-05-30 | 2026-05-30 | Quarterly Result Announcement | NA | 28.92% |
| 2026-05-12 | 2026-05-12 | Extraordinary General Meeting | NA | -2.64% |
| 2026-02-14 | 2026-02-14 | Quarterly Result Announcement | NA | -1.68% |
| 2025-11-14 | 2025-11-14 | Quarterly Result Announcement | NA | 1.36% |
| 2025-09-30 | 2025-09-30 | Annual General Meeting | NA | -0.44% |
| 2025-08-14 | 2025-08-14 | Quarterly Result Announcement | NA | -4.23% |
| 2025-05-30 | 2025-05-30 | Quarterly Result Announcement | NA | 5.19% |
| 2025-02-14 | 2025-02-14 | Quarterly Result Announcement | NA | -6.70% |
| 2024-11-14 | 2024-11-14 | Quarterly Result Announcement | NA | -5.88% |
| 2024-09-30 | 2024-09-30 | Annual General Meeting | NA | 27.26% |
| 2023-12-30 | 2023-12-30 | Extraordinary General Meeting | NA | 4.41% |
| 2022-07-21 | 2022-07-22 | Rights | 1:2 | 2.40% |
Gennex Laboratories Competitors Screener - Peer Comparison
Screen GENNEX competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 441,478 | 36.91 | 61,674 | 12.69% | 11,565 | 34.00 |
| Divis Laboratories | 247,470 | 85.36 | 11,067 | 13.95% | 2,568 | 63.65 |
| Torrent Pharmaceuticals | 188,872 | 86.95 | 13,886 | 20.34% | 2,138 | 52.16 |
| Zydus Life Science | 112,608 | 24.28 | 27,658 | 17.64% | 5,026 | 45.64 |
| Cipla | 110,352 | 33.22 | 29,045 | 2.24% | 3,870 | 35.27 |
| Laurus Labs | 106,298 | 95.94 | 6,868 | 22.01% | 890 | 68.28 |
| Dr Reddys Laboratories | 97,281 | 29.91 | 35,059 | 3.90% | 4,158 | 47.72 |
| Aurobindo Pharma | 96,652 | 25.88 | 34,145 | 5.56% | 3,503 | 57.04 |
| Lupin | 95,790 | 17.09 | 29,039 | 26.75% | 5,356 | 28.17 |
| Mankind Pharma | 94,163 | 44.87 | 14,636 | 14.85% | 1,938 | 37.57 |
Gennex Laboratories Company Announcements - News Screener
Screen GENNEX latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-09-15 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-09-14 | Approval Of Additional Products From Drugs Control Administration Government Of Andhra Pradesh For Our Subsidiary Company Deccan Remedies Limited | - |
| 2026-09-14 | Reg. 34 (1) Annual Report. | - |
| 2026-09-10 | Intimation Of Book Closure For The Purpose Of 41St AGM Of Gennex Laboratories Limited | - |
| 2026-09-10 | Board Meeting Outcome for Meeting Held On September 04 2026 | - |
| 2026-08-27 | Board Meeting Intimation for For Fixing Date Time And Venue Of 41St AGM Of The Company | - |
| 2026-08-17 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-14 | Un-Audited Financial Results For The Quarter Ended June 30 2026 | - |
| 2026-08-14 | Board Meeting Outcome for Un-Audited Financial Results For The Quarter Ended June 30 2026 | - |
| 2026-07-30 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-07-29 | Board Meeting Intimation for Consideration And Approval Of The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended June 30 2026. | - |
| 2026-07-17 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-06-23 | Closure of Trading Window | - |
| 2026-06-10 | Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations 2011. | - |
| 2026-06-10 | Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations 2011. | - |
| 2026-06-10 | Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011. | - |
| 2026-06-10 | Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011. | - |
| 2026-06-10 | Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011. | - |
| 2026-06-01 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-05-30 | Financial Result For The Quarter And Year Ended March 31 2026 | - |